RXRX250110C5000
- 2.05
- 0.000.00%
Recursion Pharmaceuticals Newsroom
Cathie Wood's ARK Investment Buys 653K Shares of Recursion Pharmaceuticals Today
Recursion Pharmaceuticals Is Maintained at Overweight by Keybanc
Recursion Pharmaceuticals Analyst Ratings
KeyBanc Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10
KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating
"Nvidia Magic" Strikes Again! Exploring Nvidia's Latest AI Investment Landscape
BofA Securities Cuts Price Target on Recursion Pharmaceuticals to $10 From $12, Maintains Neutral Rating
Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More
Express News | Recursion Pharmaceuticals Inc - First Patient to Be Dosed in Phase 1 Excelerize Trial in Q1 2025
Express News | Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
Trending Industry Today: Serve Robotics Leads Gains In NVIDIA Portfolio Stocks
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
Trending Industry Today: Nano X Imaging Leads Gains In NVIDIA Portfolio Stocks
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 30% Share Price Surge Not Quite Adding Up
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Trending Industry Today: Arm Holdings Leads Losses In NVIDIA Portfolio Stocks